Multiparametric Flow Cytometry (MFC)
MFC utilizes fluorescently labeled antibodies and dyes to assess biological molecules within or on the surface of cells. This technique serves as a cornerstone for diagnosis of hematolymphoid neoplasms, swiftly identifying abnormal blast populations, characterizing blast lineages, and assessing clonality.
LabPMM’s Global Network offers highly sensitive MFC assays for prognostication and risk stratification, providing reproducible and precise results for clinically relevant outcomes in chronic and acute hematolymphoid neoplasia.
Globally Standardized Multiparametric Flow Cytometry (MFC) Assays
MFC stands out as a superior tool for diagnosing and monitoring hematological malignancies due to its high sensitivity and specificity, rapid turnaround time, quantitative analysis capabilities, comprehensive immunophenotyping, and standardization. While other technologies like IHC, cytogenetics, and molecular techniques have their strengths, MFC provides a unique combination of advantages that make it indispensable in the clinical management of hematological malignancies.
Our internationally harmonized MFC assays are designed for bone marrow and peripheral blood and are based on guidelines such as 2018 ELN MRD Working Party Consensus, 2006 Bethesda Consensus, European Research Initiative on CLL (ERIC), and 2017 WHO Classification Guidance.
References | Wood et al. Cytometry B: Clin. Cytom. 2007. 72(S1),S14,S22. | Swerdlow et al. WHO Classification of Tumors, (Revised 4th Edition) IARC: Lyon, 421 (2017) | Orfao et al. Haematologica. 2004. 89(9):1128-1135. | San Miguel et al. Haematologica. 2002. 87(11):1135-1144. | FE Craig and KA Foon. Blood. 2008. 111(8):3941-3967. | Davis et al. Leukemia. 2007. 21(5):1144-1160. | Seegmiller et al. Am. J Clin. Path. 2009. 132(4):549-556. | Döhner et al. Blood. 2017. 129(4):424-447. | A Rawstron. (2021) ERIC guidelines for MRD assessment in CLL 2021. [PowerPoint presentation]. Available at http://www.ericll.org/wp-content/uploads/2021/09/ERIC-ELN-Mannheim-Update-on-cellular-MRD-guidelines_Andy-Rawstron.pdf
LabPMM’s Global Network offers highly sensitive MFC assays for prognostication and risk stratification, providing reproducible and precise results for clinically relevant outcomes in chronic and acute hematolymphoid neoplasia.
Globally Standardized Multiparametric Flow Cytometry (MFC) Assays
MFC stands out as a superior tool for diagnosing and monitoring hematological malignancies due to its high sensitivity and specificity, rapid turnaround time, quantitative analysis capabilities, comprehensive immunophenotyping, and standardization. While other technologies like IHC, cytogenetics, and molecular techniques have their strengths, MFC provides a unique combination of advantages that make it indispensable in the clinical management of hematological malignancies.
Our internationally harmonized MFC assays are designed for bone marrow and peripheral blood and are based on guidelines such as 2018 ELN MRD Working Party Consensus, 2006 Bethesda Consensus, European Research Initiative on CLL (ERIC), and 2017 WHO Classification Guidance.
References | Wood et al. Cytometry B: Clin. Cytom. 2007. 72(S1),S14,S22. | Swerdlow et al. WHO Classification of Tumors, (Revised 4th Edition) IARC: Lyon, 421 (2017) | Orfao et al. Haematologica. 2004. 89(9):1128-1135. | San Miguel et al. Haematologica. 2002. 87(11):1135-1144. | FE Craig and KA Foon. Blood. 2008. 111(8):3941-3967. | Davis et al. Leukemia. 2007. 21(5):1144-1160. | Seegmiller et al. Am. J Clin. Path. 2009. 132(4):549-556. | Döhner et al. Blood. 2017. 129(4):424-447. | A Rawstron. (2021) ERIC guidelines for MRD assessment in CLL 2021. [PowerPoint presentation]. Available at http://www.ericll.org/wp-content/uploads/2021/09/ERIC-ELN-Mannheim-Update-on-cellular-MRD-guidelines_Andy-Rawstron.pdf
This panel characterizes and identifies all major white blood cell lineages and major types of hematopoietic neoplasia.
Diagnose and Stratify
Hematologic malignancies (HMs) are the fourth most frequently diagnosed cancer in economically developed countries. Over the past decade, the number of clinical trials targeting HMs has increased at a rapid rate, perpetually changing the diagnostic and therapeutic paradigm.
MFC is essential in diagnosing various hematologic malignancies by detecting abnormal antigen expression on cell surfaces. It can distinguish between different cell lineages and stages of maturation, which is critical for identifying specific types of leukemia and lymphoma. The Hematolymphoid Screening Panel identifies biomarkers useful for targeted therapies as well as clinical trial screening and patient enrollment.
References | Döhner et al. Blood. 2017;129(4):424-447. | Porwit A, Béné MC, eds. Multiparameter Flow Cytometry in the Diagnosis of Hematologic Malignancies. Cambridge University Press; 2018. | Batista et al. Pathology and Epidemiology of Cancer. Springer, Cham; 2017. | Keykhaei et al. Exp Hematol Oncol. 2021; 10,11.
A comprehensive 12-color panel of 21 unique biomarkers to characterize potential AML blast cells using a leukemia-associated immunophenotype (LAIP) based different from normal (DfN) approach.
Residual Disease Monitoring
Overall, the incidence of AML is increasing globally, particularly in older adults and in regions with higher socio-demographic indexes, emphasizing the need for accurate monitoring of targeted interventions and guiding treatment decisions.
The presence of measurable residual disease (MRD) serves as a robust prognostic marker, guiding therapeutic stratification and treatment response assessment. By integrating MRD evaluation into post-treatment assessments, clinicians can identify high-risk patients and tailor treatment strategies accordingly. MRD assays can also be used for subject enrollment and endpoint analyses in clinical trials.
References | Ravandi et al. Blood Adv. 2018 Jun 12;2(11):1356-1366. | Döhner et al. Blood. 2017;129(4):424-447. | | A Rawstron. (2021) ERIC guidelines for MRD assessment in CLL 2021. [PowerPoint presentation]. Available at http://www.ericll.org/wp-content/uploads/2021/09/ERIC-ELN-Mannheim-Update-on-cellular-MRD-guidelines_Andy-Rawstron.pdf
A highly sensitive and targeted 11-color panel designed to characterize potential CLL cells with clear separation from other B-lineage cells.
Stratify Risk and Predict Survival
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries, with an incidence of approximately 4.9 per 100,000 people per year. The presence of measurable residual disease (MRD) serves as a robust prognostic marker, guiding therapeutic stratification and treatment response assessment.
MFC is increasingly used for MRD monitoring, which is crucial for assessing treatment efficacy, early detection of relapse, and predicting overall survival. The use of MFC to monitor MRD in patients treated with chemoimmunotherapy or targeted agents has been demonstrated that those with undetectable MRD have significantly better outcomes compared to those with detectable MRD. By integrating the CLL MRD Assay into post-treatment assessments, clinicians can identify high-risk patients and tailor treatment strategies accordingly.
References | Al-Sawaf et al. Clin. Adv Hematol Oncol. 2022; 20(2):97-103. | Dong et al. Exp Hematol Oncol. 2020 Jun 19;9:14. | Ou et al. Front Oncol. 2022 Mar; 840618.
This panel characterizes and identifies all major white blood cell lineages and major types of hematopoietic neoplasia.
Diagnose and Stratify
Hematologic malignancies (HMs) are the fourth most frequently diagnosed cancer in economically developed countries. Over the past decade, the number of clinical trials targeting HMs has increased at a rapid rate, perpetually changing the diagnostic and therapeutic paradigm.
MFC is essential in diagnosing various hematologic malignancies by detecting abnormal antigen expression on cell surfaces. It can distinguish between different cell lineages and stages of maturation, which is critical for identifying specific types of leukemia and lymphoma. The Hematolymphoid Screening Panel identifies biomarkers useful for targeted therapies as well as clinical trial screening and patient enrollment.
References | Döhner et al. Blood. 2017;129(4):424-447. | Porwit A, Béné MC, eds. Multiparameter Flow Cytometry in the Diagnosis of Hematologic Malignancies. Cambridge University Press; 2018. | Batista et al. Pathology and Epidemiology of Cancer. Springer, Cham; 2017. | Keykhaei et al. Exp Hematol Oncol. 2021; 10,11.
A comprehensive 12-color panel of 21 unique biomarkers to characterize potential AML blast cells using a leukemia-associated immunophenotype (LAIP) based different from normal (DfN) approach.
Residual Disease Monitoring
Overall, the incidence of AML is increasing globally, particularly in older adults and in regions with higher socio-demographic indexes, emphasizing the need for accurate monitoring of targeted interventions and guiding treatment decisions.
The presence of measurable residual disease (MRD) serves as a robust prognostic marker, guiding therapeutic stratification and treatment response assessment. By integrating MRD evaluation into post-treatment assessments, clinicians can identify high-risk patients and tailor treatment strategies accordingly. MRD assays can also be used for subject enrollment and endpoint analyses in clinical trials.
References | Ravandi et al. Blood Adv. 2018 Jun 12;2(11):1356-1366. | Döhner et al. Blood. 2017;129(4):424-447. | | A Rawstron. (2021) ERIC guidelines for MRD assessment in CLL 2021. [PowerPoint presentation]. Available at http://www.ericll.org/wp-content/uploads/2021/09/ERIC-ELN-Mannheim-Update-on-cellular-MRD-guidelines_Andy-Rawstron.pdf
A highly sensitive and targeted 11-color panel designed to characterize potential CLL cells with clear separation from other B-lineage cells.
Stratify Risk and Predict Survival
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries, with an incidence of approximately 4.9 per 100,000 people per year. The presence of measurable residual disease (MRD) serves as a robust prognostic marker, guiding therapeutic stratification and treatment response assessment.
MFC is increasingly used for MRD monitoring, which is crucial for assessing treatment efficacy, early detection of relapse, and predicting overall survival. The use of MFC to monitor MRD in patients treated with chemoimmunotherapy or targeted agents has been demonstrated that those with undetectable MRD have significantly better outcomes compared to those with detectable MRD. By integrating the CLL MRD Assay into post-treatment assessments, clinicians can identify high-risk patients and tailor treatment strategies accordingly.
References | Al-Sawaf et al. Clin. Adv Hematol Oncol. 2022; 20(2):97-103. | Dong et al. Exp Hematol Oncol. 2020 Jun 19;9:14. | Ou et al. Front Oncol. 2022 Mar; 840618.
